TNGX · Tango Therapeutics, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-03 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $27.17 to $27.78 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
21,733 |
| 2026-08-03 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $26.17 to $27.16 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
5,267 |
| 2026-08-03 | Crystal Adam |
President, R&D |
Convert↑
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. |
Common Stock
|
27,000 |
| 2026-08-03 | Crystal Adam |
President, R&D |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
27,000 |
| 2026-07-01 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $29.72 to $30.65 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
7,371 |
| 2026-07-01 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $28.715 to $29.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
19,629 |
| 2026-07-01 | Crystal Adam |
President, R&D |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
27,000 |
| 2026-07-01 | Crystal Adam |
President, R&D |
Convert↑
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. |
Common Stock
|
27,000 |
| 2026-06-19 | Azelby Robert |
Director, President & CEO |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-19 | Azelby Robert |
Director, President & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Common Stock
|
5,740 |
| 2026-06-19 | Azelby Robert |
Director, President & CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Stock Option (Right to Buy)
|
35,910 |
| 2026-06-05 | Rothenberg Mace |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Stock Option (Right to Buy)
|
25,000 |
| 2026-06-05 | Calhoun Lesley Ann |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Stock Option (Right to Buy)
|
25,000 |
| 2026-06-05 | Lee Sung |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Common Stock
|
570 |
| 2026-06-05 | Calhoun Lesley Ann |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Common Stock
|
4,000 |
| 2026-06-05 | Ketchum John B |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Stock Option (Right to Buy)
|
25,000 |
| 2026-06-05 | Ketchum John B |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Common Stock
|
4,000 |
| 2026-06-05 | Lee Sung |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Stock Option (Right to Buy)
|
3,570 |
| 2026-06-05 | Rothenberg Mace |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Common Stock
|
4,000 |
| 2026-06-01 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $22.60 to $23.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
20,860 |
| 2026-06-01 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $21.58 to $22.57 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
6,140 |
| 2026-06-01 | Crystal Adam |
President, R&D |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
27,000 |
| 2026-06-01 | Crystal Adam |
President, R&D |
Convert↑
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. |
Common Stock
|
27,000 |
| 2026-05-01 | Gall Matthew |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest over a three-year period at a rate of (i) 13,200 RSUs on or about May 10, 2027, (ii) 13,200 RSUs on or about May 10, 2028 and (iii) 13,600 RSUs on or about May 9, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Common Stock
|
40,000 |
| 2026-05-01 | Crystal Adam |
President, R&D |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
27,000 |
| 2026-05-01 | Gall Matthew |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable over a four-year period, at a rate of 25% on April 15, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Stock Option (Right to Buy)
|
240,000 |
| 2026-05-01 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $20.79 to $21.755 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
25,900 |
| 2026-05-01 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $21.80 to $22.20 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
1,100 |
| 2026-05-01 | Crystal Adam |
President, R&D |
Convert↑
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Includes 3,121 shares that were acquired on November 1, 2025 pursuant to the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Common Stock
|
27,000 |
| 2026-04-29 | Lee Sung |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments on January 2, 2027, January 2, 2028 and January 2, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. The RSUs were granted in connection with the Reporting Person's service on the Issuer's board of directors and reflect the value the Reporting Person is entitled to pursuant to the Issuer's Non-Employee Director Compensation Policy. |
Common Stock
|
12,300 |
| 2026-04-29 | Lee Sung |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years commencing on January 2, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. The options were granted in connection with the Reporting Person's service on the Issuer's board of directors and reflect the value the Reporting Person is entitled to pursuant to the Issuer's Non-Employee Director Compensation Policy. |
Stock Option (Right to Buy)
|
5,200 |
| 2026-04-15 | Gall Matthew |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2026-04-15 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. |
Common Stock
|
38,460 |
| 2026-04-15 | Crystal Adam |
President, R&D |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
38,460 |
| 2026-04-15 | Crystal Adam |
President, R&D |
Convert↑
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. |
Common Stock
|
38,460 |
| 2026-04-01 | Crystal Adam |
President, R&D |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
27,000 |
| 2026-04-01 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
27,000 |
| 2026-04-01 | Crystal Adam |
President, R&D |
Convert↑
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. |
Common Stock
|
27,000 |
| 2026-03-25 | Crystal Adam |
President, R&D |
Convert↑
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. |
Common Stock
|
12,000 |
| 2026-03-25 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
12,000 |
| 2026-03-25 | Crystal Adam |
President, R&D |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
12,000 |
| 2026-03-05 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. |
Common Stock
|
20,251 |
| 2026-02-25 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $12.61 to $13.09 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
54,345 |
| 2026-02-03 | Weber Barbara |
Director, Director, Executive Chair |
Sell↓
Filing footnotes — Common Stock (Direct)
The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
30,186 |
| 2026-02-03 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
201 |
| 2026-02-03 | Beckman Daniella |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
10,204 |
| 2026-02-03 | Beckman Daniella |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
113 |
| 2026-02-03 | Crystal Adam |
President, R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
18,251 |
| 2026-02-03 | Weber Barbara |
Director, Director, Executive Chair |
Sell↓
Filing footnotes — Common Stock (Direct)
The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Common Stock
|
333 |
| 2026-02-02 | Beckman Daniella |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Common Stock
|
44,330 |